Hongri Pharmaceutical Group, founded in 1996, is a high-tech pharmaceutical and health industry group with investment, R&D, production and capital across many fields such as modern Chinese medicine preparations, Chinese medicine granules, chemical synthetic medicines, biotechnology medicines, medical devices and Internet medical care, etc. In 2009, Hongri Pharmaceutical was listed on the GEM board of Shenzhen Stock Exchange (stock code 300026) and its market capitalization climbed to 22 billion yuan. In 2009, Hongri Pharmaceuticals was listed on the Shenzhen Stock Exchange GEM Board (stock code 300026), with a market capitalization of 22 billion yuan. The group has been honored on the Forbes China Potential Enterprises List for three consecutive years, and has won many awards, including China's Top 100 Pharmaceutical Manufacturing Enterprises and the 2014 China Pharmaceutical Social Responsibility Excellence Award.